GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (MEX:AZNN) » Definitions » Cyclically Adjusted Price-to-FCF

AstraZeneca (MEX:AZNN) Cyclically Adjusted Price-to-FCF : 53.65 (As of Jan. 19, 2025)


View and export this data going back to 2007. Start your Free Trial

What is AstraZeneca Cyclically Adjusted Price-to-FCF?

As of today (2025-01-19), AstraZeneca's current share price is MXN1388.99. AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 was MXN25.89. AstraZeneca's Cyclically Adjusted Price-to-FCF for today is 53.65.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

MEX:AZNN' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 14.59   Med: 39.23   Max: 73.79
Current: 55.39

During the past years, AstraZeneca's highest Cyclically Adjusted Price-to-FCF was 73.79. The lowest was 14.59. And the median was 39.23.

MEX:AZNN's Cyclically Adjusted Price-to-FCF is ranked worse than
68.14% of 295 companies
in the Drug Manufacturers industry
Industry Median: 30.3 vs MEX:AZNN: 55.39

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

AstraZeneca's adjusted free cash flow per share data for the three months ended in Sep. 2024 was MXN12.763. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is MXN25.89 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted Price-to-FCF Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.17 48.06 60.81 62.36 57.15

AstraZeneca Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.91 57.15 56.63 62.75 58.68

Competitive Comparison of AstraZeneca's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted Price-to-FCF falls into.



AstraZeneca Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AstraZeneca's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=1388.99/25.89
=53.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, AstraZeneca's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=12.763/133.5000*133.5000
=12.763

Current CPI (Sep. 2024) = 133.5000.

AstraZeneca Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 8.011 99.900 10.705
201503 -6.911 99.600 -9.263
201506 2.704 100.100 3.606
201509 8.088 100.200 10.776
201512 0.245 100.400 0.326
201603 6.035 100.400 8.025
201606 -5.994 101.000 -7.923
201609 3.398 101.500 4.469
201612 10.740 102.200 14.029
201703 -2.209 102.700 -2.871
201706 -0.578 103.500 -0.746
201709 13.536 104.300 17.326
201712 3.449 105.000 4.385
201803 -3.398 105.100 -4.316
201806 -2.280 105.900 -2.874
201809 1.476 106.600 1.848
201812 14.064 107.100 17.531
201903 -8.773 107.000 -10.946
201906 -0.703 107.900 -0.870
201909 5.733 108.400 7.060
201912 7.110 108.500 8.748
202003 -2.116 108.600 -2.601
202006 0.554 108.800 0.680
202009 9.404 109.200 11.497
202012 9.469 109.400 11.555
202103 11.352 109.700 13.815
202106 4.070 111.400 4.877
202109 7.278 112.400 8.644
202112 4.597 114.700 5.350
202203 18.297 116.500 20.967
202206 4.546 120.500 5.036
202209 11.735 122.300 12.810
202212 11.523 125.300 12.277
202303 9.608 126.800 10.116
202306 6.786 129.400 7.001
202309 12.478 130.100 12.804
202312 7.762 130.500 7.940
202403 4.686 131.600 4.754
202406 14.192 133.000 14.245
202409 12.763 133.500 12.763

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (MEX:AZNN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AstraZeneca Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca Business Description

Industry
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

AstraZeneca Headlines

No Headlines